product name SL-327
Description: SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/ 0.22μM, it has no activity towards Erk1, MKK3, MKK4, c-JUN, PKC, PKA, or CamKII. SL327 blocks acquisition but not expression of lithium-induced conditioned place aversion: a behavioral and immunohistochemical study. SL327 had no affect on acquisition, expression, or extinction of EtOH-induced CPP in mice despite causing significant reduction of pERK levels in multiple brain regions.
References: J Biol Chem. 2000 Nov 24;275(47):37086-92; J Neurosci. 2000 Dec 1;20(23):8701-9.
335.35
Formula
C16H12F3N3S
CAS No.
305350-87-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 67 mg/mL (199.8 mM)
Water: <1 mg/mL
Ethanol: 7 mg/mL (20.9 mM)
Solubility (In vivo)
2% DMSO+30% PEG 300+5% Tween 80+ddH2O: 5 mg/mL
Synonyms
other peoduct :
| In Vitro |
In vitro activity: SL327 is a water soluble, structural homologue of the specific MKK1/2 inhibitor U0126 with IC50 of 0.18 μM and 0.22 μM for MEK1 and MEK2 respectively. SL327 has no effect on a variety of other kinases, including PKA, PKC, or CamKII. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | SL327 (50 mg/kg) crosses the blood-brain barrierand and blocks fear conditioning by inhibiting MAPK/ERK phosphorylation. SL327 (30 mg/kg) significantly impairs spatial learning in mice. SL327 (50 mg/kg) blocks cocaine-induced properties |
| Animal model | Fear conditioning experiments in male Spague-Dawley rats. |
| Formulation & Dosage | Dissolved in DMSO; 10-100 mg/Kg; i.p. injection |
| References | J Biol Chem. 2000 Nov 24;275(47):37086-92; J Neurosci. 2000 Dec 1;20(23):8701-9. |
